Table 2.

HPV16 seronegativity among the bivalent vaccine recipients (BVR) and quadrivalent vaccine recipients (QVR) (including only the samples with the shortest lag)

	HPV16 seronegativity among trial participants 1–12 years post-vaccination with 3 doses, n/N (%)
	Neutralising antibodies (PBNA)	Total binding antibodies (Luminex)	PBNA & Luminex	Kappa, κ
All vaccine recipients	13/648 (2.00%)	15/648 (2.31%)	13/648 (2.00%)	0.93 (0.83–1.00)
Quadrivalent vaccine recipients	13/328 (3.96%)	15/328 (4.57%)	13/328 (3.96%)	0.93 (0.82–1.00)
Bivalent vaccine recipients	0/320 (0.00%)	0/320 (0.00%)	0/320 (0.00%)	-

Cohen’s Kappa coefficient comparing the results from the PBNA to that from the Luminex immunoassay. *HPV16 seronegative as measured both with the PBNA and the Luminex immunoassay.